Son of Darzalex hits the skids
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Amgen looks for Five Prime payback
A key pivotal study of bemarituzumab will read out shortly.
